Literature DB >> 18664591

G protein coupling and signaling pathway activation by m1 muscarinic acetylcholine receptor orthosteric and allosteric agonists.

Rachel L Thomas1, Rajendra Mistry, Christopher J Langmead, Martyn D Wood, R A John Challiss.   

Abstract

The M(1) muscarinic acetylcholine (mACh) receptor is among a growing number of G protein-coupled receptors that are able to activate multiple signaling cascades. AC-42 (4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl] piperidine) is an allosteric agonist that can selectively activate the M(1) mACh receptor in the absence of an orthosteric ligand. Allosteric agonists have the potential to stabilize unique receptor conformations, which may in turn cause differential activation of signal transduction pathways. In the present study, we have investigated the signaling pathways activated by AC-42, its analog 77-LH-28-1 (1-[3-(4-butyl-1-piperidinyl)propyl]-3,4-dihydro-2(1H)-quinolinone), and a range of orthosteric muscarinic agonists [oxotremorine-M (oxo-M), arecoline, and pilocarpine] in Chinese hamster ovary cells recombinantly expressing the human M(1) mACh receptor. Each agonist was able to activate Galpha(q/11)-dependent signaling, as demonstrated by an increase in guanosine 5'-O-(3-thiotriphosphate) ([(35)S]GTPgammaS) binding to Galpha(q/11) proteins and total [(3)H]inositol phosphate accumulation assays in intact cells. All three orthosteric agonists caused significant enhancements in [(35)S]GTPgammaS binding to Galpha(i1/2) subunits over basal; however, neither allosteric ligand produced a significant response. In contrast, both orthosteric and allosteric agonists are able to couple to the Galpha(s)/cAMP pathway, enhancing forskolin-stimulated cAMP accumulation. These data provide support for the concept that allosteric and orthosteric mACh receptor agonists both stabilize receptor conformations associated with Galpha(q/11)- and Galpha(s)-dependent signaling; however, AC-42 and 77-LH-28-1, unlike oxo-M, arecoline, and pilocarpine, do not seem to promote M(1) mACh receptor-Galpha(i1/2) coupling, suggesting that allosteric agonists have the potential to activate distinct subsets of downstream effectors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18664591     DOI: 10.1124/jpet.108.141788

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  21 in total

1.  A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation.

Authors:  Meritxell Canals; J Robert Lane; Adriel Wen; Peter J Scammells; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2011-11-15       Impact factor: 5.157

Review 2.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 3.  Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.

Authors:  Gregory J Digby; Jana K Shirey; P Jeffrey Conn
Journal:  Mol Biosyst       Date:  2010-06-25

4.  Distinct profiles of functional discrimination among G proteins determine the actions of G protein-coupled receptors.

Authors:  Ikuo Masuho; Olga Ostrovskaya; Grant M Kramer; Christopher D Jones; Keqiang Xie; Kirill A Martemyanov
Journal:  Sci Signal       Date:  2015-12-01       Impact factor: 8.192

5.  Contrasting effects of allosteric and orthosteric agonists on m1 muscarinic acetylcholine receptor internalization and down-regulation.

Authors:  Rachel L Thomas; Christopher J Langmead; Martyn D Wood; R A John Challiss
Journal:  J Pharmacol Exp Ther       Date:  2009-09-18       Impact factor: 4.030

Review 6.  Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.

Authors:  Briana J Davie; Arthur Christopoulos; Peter J Scammells
Journal:  ACS Chem Neurosci       Date:  2013-05-23       Impact factor: 4.418

7.  Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey.

Authors:  Joshua D Vardigan; Christopher E Cannon; Vanita Puri; Mandy Dancho; AmyJo Koser; Marion Wittmann; Scott D Kuduk; John J Renger; Jason M Uslaner
Journal:  Psychopharmacology (Berl)       Date:  2014-12-10       Impact factor: 4.530

8.  Bladder urothelial cells from patients with interstitial cystitis have an increased sensitivity to carbachol.

Authors:  Gopal N Gupta; Shao-Gang Lu; Michael S Gold; Toby C Chai
Journal:  Neurourol Urodyn       Date:  2009       Impact factor: 2.696

9.  Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation.

Authors:  Lei Ma; Matthew A Seager; Matthew Seager; Marion Wittmann; Marlene Jacobson; Denise Bickel; Maryann Burno; Keith Jones; Valerie Kuzmick Graufelds; Guangping Xu; Michelle Pearson; Alexander McCampbell; Renee Gaspar; Paul Shughrue; Andrew Danziger; Christopher Regan; Rose Flick; Danette Pascarella; Susan Garson; Scott Doran; Constantine Kreatsoulas; Lone Veng; Craig W Lindsley; William Shipe; Scott Kuduk; Cyrille Sur; Gene Kinney; Guy R Seabrook; William J Ray
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-26       Impact factor: 11.205

10.  Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands.

Authors:  Christopher N Davis; Stefania Risso Bradley; Hans H Schiffer; Mikael Friberg; Kristian Koch; Bo-Ragnar Tolf; Douglas W Bonhaus; Jelveh Lameh
Journal:  BMC Pharmacol       Date:  2009-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.